Formerly known as Spyryx LLC., Spyryx Biosciences is a clinical-stage company developing novel therapeutics to address severe pulmonary indications. SpyryxÂ’s lead candidate, SPX-101, is in Phase 2 clinical testing for cystic fibrosis. The product has demonstrated a robust ability to restore mucociliary clearance in animal models of the disease and has the potential to improve lung function for all people with CF, regardless of their CFTR mutation. The Spyryx team has extensive experience in the development of respiratory medicines and works closely with a broad group of experts in the pulmonary field. The Company is VC funded and also has a development award from the Cystic Fibrosis Foundation.
